Literature DB >> 7286579

Furosemide disposition in cirrhotic patients.

V K Sawhney, P B Gregory, S E Swezey, T F Blaschke.   

Abstract

Furosemide disposition in 7 cirrhotic subjects and 4 age-matched healthy controls was studied to determine the contribution of differences in pharmacokinetics to the decreased responsiveness observed in cirrhotics. Subjects were given 80 mg of furosemide orally and intravenously on separate occasions, and plasma and urine samples were collected and analyzed for furosemide by high performance liquid chromatography. The half-life of furosemide was 74% greater in the cirrhotic subjects, the result of a smaller increase in volume of distribution (30%) and a decrease in total plasma clearance (15%). The change in plasma clearance was due entirely to a change in nonrenal clearance, since renal clearance was very similar in both groups. The fraction of furosemide not bound to plasma proteins increased by 48%. Furosemide bioavailability was the same in cirrhotic subjects and controls. Consistent with other reports, there was considerable intersubject variability in all of the measured and computed parameters. The results show that differences in disposition play little, if any, role in the decreased renal responsiveness to furosemide.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7286579

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  17 in total

1.  Clinical Pharmacology in Diuretic Use.

Authors:  David H Ellison
Journal:  Clin J Am Soc Nephrol       Date:  2019-04-01       Impact factor: 8.237

Review 2.  Furosemide (frusemide). A pharmacokinetic/pharmacodynamic review (Part II).

Authors:  L L Ponto; R D Schoenwald
Journal:  Clin Pharmacokinet       Date:  1990-06       Impact factor: 6.447

Review 3.  Guide to drug dosage in hepatic disease.

Authors:  N M Bass; R L Williams
Journal:  Clin Pharmacokinet       Date:  1988-12       Impact factor: 6.447

Review 4.  Resistance to loop diuretics. Why it happens and what to do about it.

Authors:  D C Brater
Journal:  Drugs       Date:  1985-11       Impact factor: 9.546

Review 5.  Dose adjustment in patients with liver disease.

Authors:  Fabiola Delcò; Lydia Tchambaz; Raymond Schlienger; Jürgen Drewe; Stephan Krähenbühl
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

6.  Torasemide in the treatment of patients with cirrhosis and ascites.

Authors:  P Gentilini; G Laffi; G La Villa; V Carloni; M Foschi; R G Romanelli; F Marra
Journal:  Cardiovasc Drugs Ther       Date:  1993-01       Impact factor: 3.727

7.  Comparative pharmacokinetics and cardiovascular effects of tiapamil in healthy volunteers and patients with hepatic cirrhosis.

Authors:  P H Hinderling; M Eckert; S Gasic; H G Eichler; R Pötzi; P Heizmann
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 8.  Pharmacotherapy of ascites associated with cirrhosis.

Authors:  P Ginès; V Arrovo; J Rodés
Journal:  Drugs       Date:  1992-03       Impact factor: 9.546

9.  Extrahepatic metabolism of frusemide in anaesthetized rabbits.

Authors:  J Vergés; L Héroux; H Maurice; P du Souich
Journal:  Br J Pharmacol       Date:  1995-11       Impact factor: 8.739

10.  An intensive drug monitoring study suggesting possible clinical irrelevance of impaired drug disposition in liver disease.

Authors:  C A Naranjo; U Busto; E Janecek; I Ruiz; C A Roach; K Kaplan
Journal:  Br J Clin Pharmacol       Date:  1983-04       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.